Micropulse Cyclophotocoagulation: Initial Results in Refractory Glaucoma.

Area of Science:

• Ophthalmology
• Glaucoma Treatment
• Medical Devices

Background:

• Glaucoma is a leading cause of irreversible blindness worldwide.
• Uncontrolled intraocular pressure (IOP) is a primary risk factor for glaucoma progression.
• Traditional cyclophotocoagulation (CPC) can be effective but carries risks of complications.

Purpose of the Study:

• To evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) in patients with uncontrolled glaucoma.
• To assess the impact of MP-TSCPC on intraocular pressure (IOP) and medication requirements.
• To determine MP-TSCPC's suitability as an alternative to traditional glaucoma surgeries.

Main Methods:

• Retrospective chart review of patients undergoing MP-TSCPC at Glaucoma Associates of Texas.
• Analysis of pre- and post-operative intraocular pressure (IOP) and medication usage.
• Documentation of treatment outcomes, including IOP reduction, medication changes, and complications.

Main Results:

• MP-TSCPC significantly reduced mean IOP from 27.7 mm Hg to 16.3 mm Hg (41.2% reduction) at 1 month post-procedure, with sustained reduction over 12 months.
• Mean ocular antihypertensive medication use decreased from 3.3 to 1.9 at 1 month.
• Complications included hypotony, IOP spike, hyphema, choroidal detachment, inflammation (46% at 3 months), and vision loss (41% at 3 months). Five patients required further intervention.

Conclusions:

• MP-TSCPC is an effective treatment for lowering IOP and reducing medication burden in uncontrolled glaucoma.
• It serves as a reasonable and effective alternative for patients with limited visual potential or high risk for incisional surgery.
• Further studies and longer follow-up are needed to fully establish long-term outcomes and safety profiles.